Remix Therapeutics secures $100M and a reverse merger

Watertown biotech Remix Therapeutics secures $100 million in private placement financing and will merge with Passage Bio to ...
BioPharma Dive

Remix to go public in reverse merger with once high-flying Passage Bio

The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer ...
Fierce Biotech

Spurned by FDA, Passage Bio finds exit through merger with Remix

Passage Bio, the Philadelphia-based gene therapy outfit that launched a strategic review earlier this year after tough feedback from the FDA, has found an exit in an ...

Passage Bio and Remix Therapeutics Announce Merger Agreement

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin ...